ArticleThe Indian journal of medical research2025
Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Deciphering the prognostic weight of tumour-cell CTLA-4 in gastric carcinoma: The need for molecular stratification.The Indian journal of medical research · 2026Article
- Authors' Response.The Indian journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives Immune checkpoint inhibitor (ICI) therapy is an emerging therapeutic strategy for several malignancies, including gastric cancer, that hinges on immune checkpoint expression by the tumour infiltrating lymphocytes (TILs). Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is a well-known inhibitory T-cell co-receptor that functions as an immune checkpoint. CTLA-4 has also been found to be expressed by tumour cells making it a potential area of research for targeted therapy. We attempted to explore tumour cell CTLA-4 expression, and its correlation with programmed cell death receptor-1 (PD-1) and CD8 expression by the TILs and their correlations with histopathological parameters in gastric carcinoma. Methods A retrospective study carried out on archived paraffin blocks from 50 cases of gastric adenocarcinoma. Immunohistochemical (IHC) staining was performed and interpreted by grading the marker expression on the basis of its intensity and proportion of tumour cells stained. The relationship between tumour cell CTLA-4 expression, PD-1, CD8 expression in TILs and the histopathological features of gastric carcinoma was evaluated statistically. Results Most patients (n=37, 74%) were males and aged >60 yr (n=22, 44%). A statistically significant association was noted between high CTLA-4 expression in tumour cells and higher tumour stage (P=0.017). All cases with high CTLA-4 expression in tumour cells demonstrated nodal metastasis. CTLA-4 did not show a statistically meaningful association with other histopathological parameters. Positive PD-1 expression in TILs did not show a significant association with tumour aggression in terms of tumour grade, histologic type, nodal metastasis, lymphovascular and perineural invasion. Most TILs were found to be CD8+ T-cells. Interpretation & conclusions A higher CTLA-4 expression in tumour cells is linked to advanced tumour stage in our study. These findings can trigger research to elucidate a likely role of these markers as independent prognostic and therapeutic factors in determining overall outcome in gastric carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.